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a b s t r a c t
Introduction: There is a lack of knowledge about Health-Related Quality of Life (HRQL) of Aboriginal Australians with self-reported hepatitis C infection in Western Australia. This marginalised group of people
is disproportionally affected by the hepatitis C virus (HCV) for which there is no preventative vaccine.
This study provides data that help understand the long-term consequences of living with HCV infection
within the Aboriginal community. It outlines opportunities for nursing interventions for hepatitis care
that focus on supporting mental health and drug and alcohol issues within this population.
Methods: We surveyed 123 Aboriginal people living with HCV in a community setting. Survey data
included demographics, drug use history, length of time since diagnosis, changes in lifestyle since diagnosis, fatigue, social support, alcohol consumption, and physical and mental health measures.
Results: Most participants reported amphetamine injecting frequently in the last six months and their
duration of injecting drug ranged from 8 to more than 11 years. Additionally, half of the participants
were classiﬁed as high-risk alcohol users. Overall 52% of participants were in poor physical and 60% of
participants were in poor mental health.
Discussion: This survey of Aboriginal people with self-reported hepatitis C infection indicates substantial
problems of mental and physical comorbidities among this population.
Conclusion: There is a need for the development of HCV community clinics in Aboriginal health care
settings with trained Aboriginal community health nurses to reduce problematic alcohol consumption,
assess liver health and subsequently provide HCV treatment in a culturally appropriate way.
© 2019 Australian College of Nursing Ltd. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Summary of Relevance
Problem or Issue
Evidence suggests Aboriginal Australians are disproportionately affected by hepatitis C and this has a negative impact on physical and
mental quality of life. This study examined potential predictors of health-related quality of life (HRQL) in Aboriginal Australians with a
history of injecting drug use and currently living with hepatitis C.
What is Already Known
In this study we found that high levels of alcohol use; being more recently diagnosed with hepatitis C (between 1–4 years), using
methamphetamine and fatigue were the most common factors associated with poor mental and physical health among Aboriginal
Australians.
What this Paper Adds
Our ﬁndings support the integration of nursing interventions that can monitor and track HRQL over time for Aboriginal Australians
living with hepatitis C.
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1. Introduction
Hepatitis C virus infection (HCV) is a signiﬁcant public health
concern, affecting 170 million people worldwide (WHO, 2015).
Given the recent advances in hepatitis C treatment mean the
current number of people living with HCV has been reduced to
approximately 201,416 people (The Kirby Institute, 2018). The
Aboriginal Australian and Torres Strait Islander peoples (hereafter
Aboriginal Australians) comprise 3̃% of Australia’s population and
are over-represented in the prevalence of HCV as well as the incidence of newly reported HCV cases (Graham, Harrod, Iversen, &
Hocking, 2016). Approximately 16,000 Aboriginal Australians were
infected with chronic HCV in 2008, representing 8.3% of the total
population infected with HCV in Australia (McNally & Latham,
2009). More recent data also indicate that in 2015, HCV rates among
Aboriginal Australians were four times higher than among nonAboriginals (The Kirby Institute, 2016). This can be explained by the
higher number of HCV case detections for Aboriginal Australians
who inject drugs and those who are in custodial settings (Lafferty,
Treloar, Chambers, Butler, & Guthrie, 2016). Recent research suggests that the rate of newly diagnosed HCV among Aboriginal
Australians is 115 per 100,000 compared to the non-Aboriginal
rate of 40 per 100,000 (The Kirby Institute, 2016). Aboriginal
people experience disadvantage across a range of health and socioeconomic outcomes (Mitrou et al., 2014), which may also mean
unequal access to health facilities to help manage health problems
associated with HCV.
It has been suggested that the impact of a HCV diagnosis alone
causes a reduction in HRQL (Groessl et al., 2008). HCV infection
may be associated with impairment in health-related quality of
life (HRQL) (Strauss & Teixeira, 2006) even in the absence of liver
disease the impact of HCV seems to be most signiﬁcant in mental
and physical functioning. For example, a considerable reduction in
HRQL was found in HCV-positive blood donors who were unaware
of their status (Strauss, Porto-Ferreira, Almeida-Neto, & Teixeira,
2014). More recently, a treatment study with people newly infected
with HCV found signiﬁcant associations between higher physical
HRQL and employment and lower physical HRQL and symptomatic
acute infection, while lower levels of mental HRQL were associated
with a history of injecting drugs (Doyle et al., 2016).
The burden of HCV can be exacerbated by the impact it has on
HRQL. HRQL is a multidimensional concept and refers to a patient’s
subjective assessment or perception of the impact of illness and/or
its treatment on physical, mental, and social well-being (Zautra &
Goodhart, 1979). Assessing HRQL and the associated factors are
important for identifying ways to improve individual health for
those living with HCV (Mahmoud, Shaﬁk, & Attya, 2013), especially
in populations who have poor health outcomes, such as Aboriginal
people (Graham et al., 2016). Improving HRQL for individuals living
with chronic HCV can bring nurses to the front line in providing HCV
care, treatment, and support services (Lloyd et al., 2013). The evidence suggests that nurses can provide guidance and indeed lead
to the management of HCV care and treatment (Ahern, Imperial, &
Lam, 2004).
Educating individuals with HCV infection has been shown
to improve HRQL through lifestyle changes initiated through
behavioural modiﬁcation (Mahmoud et al., 2013). For example, education on the monitoring of symptoms such as fatigue,
body pain, depression, and lack of ability to function effectively
(Mahmoud et al., 2013). Previous research has shown that individuals chronically infected with HCV respond to interventions focused
on increasing knowledge and this, in turn, improves functional status and HRQL of individuals with chronic HCV (Sharif, Mohebbi,
Tabatabaee, Saberi-Firoozi, & Gholamzadeh, 2005).
While little attention has been given to the delivery of effective
HCV care in a culturally sensitive manner for Australian Aboriginal
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people, it is well understood that the absence of appropriate cultural respect can be a barrier to providing appropriate care (North
Coast Area Health Service, 2009). Cultural respect involves: “being
aware that Aboriginal culture differs from non-Aboriginal culture, and
that this culture may impact on the way that health and illness are
perceived, how Aboriginal people communicate, and which services
they are willing to access” (North Coast Area Health Service, 2009,
31). Community health nurses are well placed to play a key role
in the provision of culturally sensitive HCV care. Despite previous research examining HRQL in people living with HCV, there
are no published studies speciﬁcally examining the impact of HCV
on HRQL among Aboriginal Australians. To date, considerations of
HRQL have not been a focus in the development of HCV intervention
strategies for Aboriginal Australians with chronic HCV.
1.1. Aim
This study aimed to examine what factors predict HRQL among
Aboriginal people with a history of injecting drugs and who are
living with chronic HCV. Knowing this will inform strategies for
monitoring the physical and mental health of Aboriginal drug injectors over time.
2. Methods
2.1. Setting
Participants were recruited through multiple sites across the
Perth metropolitan area. These sites include the peer-based Western Australian Substance Users Association (WASUA) in Perth and
Bunbury; Hepatitis WA; WA AIDS Council (WAAC) Needle Syringe
Exchange Program (NSEP) ﬁxed site; and WAAC NSEP mobile
van services, operating in eight locations in the metropolitan
area (Rockingham, Mirrabooka, Joondalup, Midland, Forrestﬁeld,
Armadale, Fremantle and Gosnells).
2.2. Sampling
The level of HRQL was used to determine the sample size; this
study used the higher proportion of 50%, that is, it was assumed
that 50% of the sample would have poor HRQL and 50% would not
have poor HRQL. By an acceptable sampling error of 9% at a 95%
level of conﬁdence (de Vaus, 1991) and employing the following
formula (Kirkwood, 2000), the overall sample is:
n (1 − n)
50 (100 − 50)
=
= 123
e2
4.52
where n is the proportion and e the required size of standard error.
Sampling error is two standard errors.
2.3. Participants
Current drug injectors who self-identiﬁed as Aboriginal and/or
Torres Strait Islander and living with HCV were invited to participate in a cross-sectional survey. The eligibility criteria for study
participants included: being 18 or more years of age; current injecting drug use; self-reported as having received an HCV diagnosis by
a health care professional more than six months prior to interview;
no previous experience of HCV treatment; and currently living in
Western Australia. The main reason for choosing those with no
experience of HCV treatment was to better understand how currently living with HCV can impact on both mental and physical
HRQL.
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2.4. Data collection
The survey was used to collect information from the 123 participants. Recruitment was undertaken through the distribution
of study posters and information sheets at the venues previously
described, and potential participants contacted the researcher
directly by phone where eligibility was determined and a mutually agreeable time was arranged to complete the questionnaire.
Consent was obtained, and the questionnaires were completed in a
private room at the recruitment site inside or in the WAAC mobile
van, or next to the mobile van wherever they felt comfortable and
safe reading and responding to the questions. Participants were recompensed for their time and expertise with a supermarket voucher
valued at AU $20 on completion of the questionnaire.
2.5. Measures
2.5.1. Independent variables
The survey was adapted from validated survey instruments and
included: socio-demographic and drug-history (Loxley, Carruthers,
& Bevan, 1995), changes in lifestyle since HCV diagnosis (Horwitz,
Brener, & Treloar, 2012), length of time since diagnosis (McNally,
Sievert, & Pitts, 2006), fatigue (Fábregasa et al., 2013) and social support (Zimet, Dahlem, Zimet, & Farley, 1988). Alcohol consumption
was measured using the AUDIT-C scale (Bush, Kivlaham, Mcdonell,
Fihn, & Bradley, 1998).
The ﬁrst section (socio-demographic and drug history) contained questions about age, gender, accommodation, level of
education, marital status, history of incarceration, residency status,
drug use duration, frequency of injection and drug preference. Age
in years was converted into a binary variable using the median score
as the cut off (Tolmie, Muijs, & McAteer, 2011), <38 years old and
≥38. All participants selected heroin or amphetamine as their preferred drug and the drug that they had injected recently, also they
reported injecting drugs for “8–10” years or “more than 11 years”
and reported injecting drugs either “once a day” or “more than once
a day”, therefore the duration of injecting and frequency of injection
was re-categorised accordingly. Alcohol consumption was assessed
with 3 items (the ﬁrst three questions of the full AUDIT). Alcohol
consumption scores greater than 3, and 4 indicate high-risk consumption among women and men, respectively (Bush et al., 1998).
These variables are considered as covariates.
The second section on changes in lifestyle since HCV diagnosis
asked participants whether changes in their lifestyle had occurred
since HCV diagnosis. This section contained 5 items; changes in diet,
reduced or removal of alcohol, increased physical exercise, HCV
monitoring, and any use of complementary medicines. Lifestyle
changes scores were coded as a dichotomous no or yes. The items
were summed together to form lifestyle changes scales; a higher
score indicated greater behavioural changes. This section also asked
the participants the length of time since their HCV diagnosis. The
third section, on family/friend support, asked whether participants
had support if they chose to undergo HCV treatment, which was
measured by 8 items. For analysing social support, scores were
grouped as “disagree” (grouping together the ﬁrst three responses)
and “agree” (the last two answers); the response “neutral” was
included in the ﬁrst group as it indicated that the subject did not
necessarily agree (Alavi et al., 2015). Disagree and agree were recategorised into “No” and “Yes”. Fatigue was measured through the
Brief Fatigue Inventory (BFI) consisting of 10 items. Fatigues were
categorised in mild (0–3 points), moderate (4–6 points), or severe
fatigue (7–10 points) (Fábregasa et al., 2013).
2.5.2. Dependent variables
Mental and physical HRQL were measured using a 36-Item Short
Form Health Survey (SF-36), the most common generic instru-

ment for measuring HRQL and one used in previous HCV research
(Ferreiraa, Almeida-Netoa, Teixeirab, & Strauss, 2015). This instrument is based on items related to physical and mental health status
and can be applied to any disease and even to healthy subjects
across eight domains (Ferreiraa et al., 2015). The SF36 is a validated
measurement (Ferreiraa et al., 2015), which created a physical component summary (PCS) and a mental component summary (MCS).
The PCS was used to assess physical health status, consisting of four
domains; physical functioning, physical role, bodily pain, and general health perception. MCS consisted of vitality, social functioning,
emotional role, and mental health scales. PCS and MCS score ranged
from 0 (zero), corresponding to the worst health condition possible,
to 100 (one hundred), corresponding to the best possible HRQL. PCS
and MCS were categorised by the sample’s median, poor PCS and
MCS were deﬁned as having a score lower than median value, this
scoring system was adopted from the previous study (Marcuello
et al., 2012).
2.6. Data analysis
Data from the questionnaires were coded and entered into SPSS
(version 22; IBM, Chicago, USA) and cleaned prior to data analysis. Descriptive analysis was conducted to describe the background
characteristics on all variables (predictors and outcomes) in the
study, and percentage distributions for all variables were calculated
to describe the full sample of participants. Bivariate analyses were
conducted on all variables. Multivariate analyses (logistic regression) were conducted when there was more than one variable
associated with the dependent variable p < 0.10 in bivariate analyses. All covariates were entered into the models. The variables with
p < 0.10 in bivariate analyses were included as candidate measures
in the multivariate model. In the multivariate analysis, p < 0.05 was
considered for the retention of variables. The probability level of
95% was applied in all statistical tests.
2.7. Ethical considerations
Ethical approval for the study was granted by the Curtin University and Fremantle Hospital Human Research Ethics Committee
(Reference Number: 12/198 and HR 77/2012). To ensure that participants were able to provide informed consent, the objectives,
procedures, and implications of the study were explained clearly
to interested potential participants. An information sheet and consent form were offered, and participants were informed that they
were free to withdraw at any time. The primary researcher (AR)
offered a follow-up interview, as support to participants who emotionally affected by speaking about their experience. Referral made
to Hepatitis WA, where provides a support service for people with
hepatitis C. However, none of the participants expressed their interest in the follow-up interview.
3. Results
3.1. General characteristics of the study sample
Of the 123 participants who completed the survey, over threequarters were male (77.2%) and the median age of participants was
38 years. Most participants had a stable home and lived alone. The
majority (83.7%) of participants had left school at or prior to completing Year 11. Just over half of all participants (55.3%) lived in
a metropolitan area. Most participants (81.3%) described themselves as unemployed and derived their main source of income
from government beneﬁts. Heroin or methamphetamine was the
only commonly injected drugs reported by participants in the six
months prior to the interview. Almost 59% of participants had
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Table 1
Socio-demographic data of survey participants.
Characteristics
Gender
Male
Female
Median age (range)
Accommodation
Non-homeless
homeless
Education
<year 11
≥year 11
Employment
Full or part time
Government beneﬁts
Residency status
Metropolitan
Non-metropolitan
Imprisonment
Yes, not in the last 6 months
Yes, in the last 6 months
Recent injecting drug use
Heroin
Methamphetamine
Drug duration
8–10 years
More than 11 years
Frequency of injection
Once a day
More than once a day
Alcohol consumption
Low risk
High risk
Time since diagnosed
5–10
1–4
Social support
Yes
No
Positive Lifestyle change
Yes
No
Fatigue
Moderate
Severe
SF 36 domains
Mental component score, median (range)
Not poor physical health
Poor physical health
SF 36 domains
Physical component score, median (range)
Not poor physical health
Poor physical health

n

%

95
28
38(24–60)

77.2
22.8

86
37

69.9
30.1

103
20

83.7
16.3

23
100

18.7
81.3

68
55

55.3
44.7

79
44

64.2
35.8

72
51

58.5
41.5

51
72

41.5
58.5

40
83

32.5
67.5

49
74

39.8
60.2

48
75

39
61

65
58

52.8
47.2

68
55

55.3
44.7

63
60

51.2
48.7

52(52.5–40)
56
67

45.5
54.5

51 (52.5–40)
59
64

48
52

injected amphetamine, most in the last six months. More than twothirds of participants (67.5%) reported injecting more than once a
day. The duration of injecting drug use for the participants ranged
from 8 to more than 11 years. No participants reported injecting
for less than 8 years. One-third of the participants reported injecting for 8–10 years. Nearly half of the participants were classiﬁed as
high-risk alcohol users using AUDIT-C ranking, and 61% of participants had been diagnosed with HCV between 1–4 years previously.
Almost 53% of the participants reported a supportive network of
either family or friends. Less than half of participants reported no
positive lifestyle changes since diagnosis with HCV. Further characteristics of the sample are presented in Table 1.
3.2. Factors associated with mental health status
Unadjusted analyses of factors associated with poor mental
health are shown in Table 2. In adjusted analysis, unemployment
(AOR: 4.49 95% CI: 1.39,14.48), high risk alcohol use (AOR: 8.01,95%
CI: 2.37,27), being diagnosed with HCV infection between 1–4 years
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(AOR: 4.2,95% CI: 1.3,14.14), methamphetamine use (AOR: 4.3,95%
CI: 1.3,14.07) and fatigue (AOR: 8.35,95% CI: 2.47,28.22) were associated with poor mental health status.
3.3. Factors associated with physical health status
Unadjusted analyses of factors associated with the poor physical role are shown in Table 3. In adjusted analysis older age (AOR:
3.81, 95% CI: 1.22, 11.94), high risk alcohol use (AOR: 8.55, 95%
CI: 2.49,29.35), being diagnosed with HCV infection between 1–4
years (AOR: 4.5,95% CI: 1.39,14.59) methamphetamine use (AOR:
3.52,95% CI: 1.1,1.18) and fatigue (AOR: 8.13,95% CI: 2.54,26.03)
were associated with poor physical status.
4. Discussion
This cross-sectional study was conducted to determine the measures required to improve HRQL of Aboriginal Australians with
a history of injecting drugs and with chronic HCV. This study
describes the demographic, physical, and mental health characteristics of Western Australian Aboriginal individuals who were HCV
treatment naïve. To our knowledge, very few Australian studies
have assessed both the mental and physical health status of this
population within a community setting. This is the ﬁrst study to
assess HRQL in Aboriginal people who inject drugs who report being
diagnosed with HCV using the SF36 and fatigue instruments. The
data shows HRQL impairments for participants, especially in the
physical and mental components of the instruments. The impact of
an HCV diagnosis coupled with patterns of injecting drug use and
other chronic conditions may aggravate the quality of life among
HCV treatment naïve patients.
In this study, over half of the participants were classiﬁed as having poor physical (52%) and mental health (60%) status using the
SF-36 scale. We found that HRQL scores were signiﬁcantly lower
than previously recorded in recently treated chronic HCV patients
(Younossi et al., 2017). This ﬁnding indicates that Aboriginal people
who inject drugs have a reduced quality of life in physical, mental and, general health domains. This support the development of
nurse-led interventions which target improving HRQL by focusing
on physical HCV symptoms and addressing psychological needs in
a culturally client centred sensitive manner.
The multivariate analysis showed an independent association
between poor physical and mental HRQL and high-risk alcohol
use, unemployment, older age, being diagnosed with HCV infection
between 1–4 years previously, methamphetamine use and fatigue.
It has been well established that HCV infection impacts on disease
progression and other health outcomes and negatively affects physical functioning and mental health of individuals with chronic HCV
(Gao, Gao, Li, Shang, & Yu, 2013). Additionally, in this study, alcohol consumption did not change signiﬁcantly after HCV diagnosis
and may indicate participants in this study were unaware of the
impact of alcohol consumption on their health. Given its relative
affordability as well as greater social acceptability, alcohol use was
common. High levels of alcohol consumption among participants in
this study was not surprising and highlights the negative impact of
alcohol use on HRQL among people living with HCV (Costenbader,
Zule, & Coomes, 2007).
More than one-third of participants in our study showed severe
fatigue according to BFI, similar to fatigue rates reported among
HCV patients in another study (Basseri et al., 2010). An earlier study
among people with HCV-HIV co-infection identiﬁed fatigue was
associated with impairment in physical and mental HRQL domains,
and was a strong predictor of reducing HRQL (Fábregasa et al.,
2013). Fatigue among participants in our study could be associated with depression, alcohol consumption, and other drug use. An
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Table 2
Unadjusted and adjusted analyses of factors associated with mental health status.
Characteristics
Gender
Male
Female
Age
<38 years
≥38 years
Accommodation
Non-homeless
homeless
Education
<year 11
≥year 11
Employment
Full or part time
Government
beneﬁts
Residency status
Metropolitan
Non-metropolitan
Imprisonment
Not within the last 6 months
In the last 6 months
Recent injecting drug use
Heroin
Methamphetamine
Drug duration
8–10 years
More than 11 years
Frequency of injection
Once a day
More than once a day
Alcohol consumption
Low risk
High risk
Year since diagnosed
5–10
1–4
Social support
Yes
No
Fatigue
Moderate
Severe
Positive Lifestyle change
Yes
No

Not poor Mental HRQL

Poor Mental HRQ

OR (95%CI)

p-value

AOR (95%CI)

p-value

37(38.9)
19(67.9)

58(61.1)
9(32.1)

0.3(0.12,0.73

p < 0.001

39 (72.2)
17 (24.6)

15 (27.8)
52(75.4)

7.95 (3.54,17.85)

p < 0.001

44(51.2)
12 (32.4)

42(48.8)
25(67.6)

2.18 (0.97,4.89)

p = 0.05

42(40.8)
16 (80)

61(59.2)
6(30)

0.29 (0.1,0.83)

p = 0.01

51(51)
5(21.7)

49(49)
18 (78.3)

3.74(1.29,10.87)

p = 0.01

4.49(1.39,14.48)

p < 0.01

43(63.2)
13(23.6)

25(36.8)
42(76.4)

5.55(2.51,12.89)

p < 0.001

46 (58.2)
10(22.7)

33(41.8)
34(77.3)

4.73 (2.05,10.92)

p < 0.001

43 (59.7)
13 (25.5)

29(40.3)
38(74.5)

4.33 (1.97,9.51)

p < 0.001

4.3(1.3,14.07)

p < 0.01

18(35.3)
38(52.8)

33(64.7)
34(47.2)

0.48 (0.23,1.02)

p = 0.05

13 (32.5)
43 (51.8)

27(67.5)
40(48.2)

0.44(0.2,0.98)

p = 0.04

41 (83.7)
15 (20.3)

8 (16.3)
59 (79.7)

20.15(7.82,51.92)

p < 0.001

8.01(2.37,27)

p < 0.001

37(58.7)
19(31.7)

26(41.3)
41(68.3)

3.07(1.46,6.43)

p < 0.001

4.2(1.3,14.14)

p = 0.01

36(55.4)
20 (34.5)

29(44.6)
38(65.5)

2.35 (1.13,4.89)

p = 0.02

37 (58.7)
19(31.7)

26(41.3)
41 (68.3)

3.071(1.46,6.43)

p < 0.001

8.35(2.47,28.22)

p < 0.001

44(64.7)
12(21.8)

24(35.3)
43 (78.2)

6.56 (2.92,14.77)

p < 0.001

effective nursing intervention to reduce the burden of fatigue is
required. However, this cross-sectional study did not allow us to
identify the causality between these factors and depression, hence
further a prospective cohort study with a large, nationally representative sample is required to verify and enrich the results of the
present study.
Being infected with HCV was associated with lower scores
in physical and mental HRQL domains, which was expected and
similar to a previous study (Younossi et al., 2015). Age also signiﬁcantly inﬂuenced the HRQL physical domain. Older age was
independently associated with diminishing effects upon quality of
life (McDonald et al., 2013).Using methamphetamine had signiﬁcant associations with poor physical and mental HRQL (Gonzales
et al., 2009). This suggests that certain illicit drugs use may have
a greater impact on HRQL and may play a more central role in
decreasing HRQL physically and mentally. The presence of illicit
drug use could be associated with changes in mental and physical
functions of individuals. This is consistent with previous research
showing methamphetamine was associated with poorer mental
and physical quality of life (Gonzales et al., 2009). Apart from medical treatment, nurses working within Aboriginal cultural contexts

can provide supportive links to drug and alcohol counsellors and
other services to meet an individual’s needs.
Limited understanding of HCV symptoms, including lack of
symptoms, may deter Aboriginal Australians from engaging in
HCV treatment (Brener et al., 2016). Experiences of stigma and
discrimination related to HCV, injecting drug use, and particularly Aboriginality can all be intensiﬁed for Aboriginal Australians
(Brener et al., 2016) when compared to others living with HCV.
Effective HCV pre and post-test discussions, including HCV diagnosis by nurses who can provide the necessary information about
managing HCV (including referral for treatment) could help reduce
these barriers to HCV care. As many Aboriginal Australians report
more pressing health and social priorities (McNally & Latham,
2009), community nurses may be well placed to manage health
problems associated with HCV. This includes education on the
asymptomatic nature of HCV and the importance of lifestyle modiﬁcations including reducing alcohol use, maintaining a healthy
weight and ongoing medical visits to prevent or delay liver
damage (Ingrid Hickman et al., 2002). Such information and education particularly when they are provided by Aboriginal health
workers can ensure culturally appropriate HCV care. Analysis
of intervention studies should be undertaken to create HRQL
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Table 3
Unadjusted and adjusted analyses of factors associated with physical health status.
Characteristics
Gender
Male
Female
Age
<38 years
≥38 years
Accommodation
Non-homeless
homeless
Education
<year 11
≥year 11
Employment
Full or part time
Government
beneﬁts
Residency status
Metropolitan
Non-metropolitan
Imprisonment
Yes, not in the last
6 months
Yes, in the last 6 months
Recent injecting drug use
Heroin
Methamphetamine
Drug duration
8–10 years
More than 11 years
Frequency of injection
Once a day
More than once a day
Alcohol consumption
Low risk
High risk
Year since diagnosed
5–10
1–4
Social support
Yes
No
Positive Lifestyle change
Yes
No
Fatigue
Moderate
Severe

Not poor Physical HRQL

Poor Physical HRQL

OR (95%CI)

p-value

AOR (95%CI)

p-value

40(42.1)
19(67.9)

55(57.9)
9(32.1)

0.34 (0.14,0.84)

p = 0.01

40 (74.1)
19 (27.5)

14 (25.9)
50(72.5)

7.51 (3.35,16.83)

p < 0.001

3.81(1.22,11.94)

p = 0.02

46(53.5)
13 (35.1)

40(46.5)
24(64.9)

2.12 (0.95,4.71)

p = 0.06

45(43.7)
14 (70)

58(56.3)
6(30)

0.33 (0.11,0.93)

p = 0.03

53(53)
6(26.1)

47(47)
17 (73.9)

3.19 (1.16,8.77)

p = 0.02

42(61.8)
17(30.9)

26(38.2)
38(69.1)

3.61(1.7,7.66)

47 (59.5)
12(27.3)

32(40.5)
32(72.7)

3.91 (1.75,8.72)

p < 0.001

44 (61.1)
15 (29.4)

28(38.9)
36(70.6)

3.77 (1.75,8.11)

p < 0.001

3.52(1.1,11.18)

p = 0.03

19(37.3)
40(55.6)

32(62.7)
32(44.4)

0.47 (0.22,0.98)

p = 0.04

14 (35)
45(54.2)

26(65)
38(45.8)

0.45(0.2,0.99)

p = 0.04

42 (85.7)
17 (23)

7 (14.3)
57 (77)

20.11(7.65,52.87)

p < 0.001

8.55(2.49,29.35)

p < 0.001

39(61.9)
20(33.3)

24(38.1)
40(66.7)

3.2 (1.55,6.8)

p < 0.001

4.5(1.39,14.59)

p = 0.01

36(55.4)
23(39.7)

29(44.6)
35(60.3)

1.88 (0.92,3.87)

p = 0.08

43(63.2)
16(29.1)

25(36.8)
39 (70.9)

4.19 (1.95,8.98)

p < 0.001

52(34.1)
7(13.5)

19(26.8)
45(86.5)

17.59(6.77,45.67)

p < 0.001

8.13(2.54,26.03)

p < 0.001

database in order to develop HCV management program and to
measure ongoing Aboriginal HRQL in the near future. Also, promoting community-based self-management and care programs
for HCV may support and develop better physical and mental
health.
5. Limitations
There are limitations to this study, which must be noted. Firstly,
there was no serological testing to conﬁrm self-reported HCV status
as participants were primarily recruited from non-clinical settings.
However, previous studies, particularly Australian studies, indicate
good levels of validity and reliability for self-reported HCV data
(O’Keefe, Aitken, Higgs, & Dietze, 2013). To minimise this bias, we
speciﬁed receiving an HCV diagnosis by a health care professional
as an inclusion criterion for this study and this likely improved the
self-reporting accuracy. Self-reporting is also susceptible to social
desirability bias. However, SF-36 is a validated and reliable instrument which involves a mixture of both positively and negatively
worded helping to minimise this bias (Doyle et al., 2016). Also, the
survey was administered when the participant had no experience

of HCV treatment meaning their experience living with HCV was
still memorable. Thirdly, selection bias may have occurred in the
study sample, as the sample was based on convenience, not a random sample. Recruiting primarily from community-based needle
syringe programs may have led to a potential bias towards participants who had better access to health care services. To minimise
this and to increase the geographical diversity in the sample, data
was collected at three different NSP sites including Bunbury and a
mobile service visiting eight suburbs, where almost half the participants identiﬁed themselves as a non-metropolitan resident at
the time of being interviewed. The study sample was not diverse in
terms of age and duration of injection, for example, a small minority of study participants (17%) were aged below 30 years, and all
study participants had injected for more than eight years, which is
not representative of the entire population of HCV-infected Aboriginal people who inject drugs in Perth. Therefore, the ﬁndings of this
study are not generalisable to other Aboriginal people in Australia.
Another limitation was the cross-sectional study design, which it
is not possible to make any causal inference about the relationship
between the predictors and HRQL.

256

A. Rashidi et al. / Collegian 27 (2020) 250–257

6. Conclusion
In conclusion, these ﬁndings provide new insights into the quality of life of Aboriginal Australians living with chronic HCV. It shows
the impact of HCV on mental and physical health status in Aboriginal people who inject drugs with chronic HCV. This study conﬁrms a
need for nursing interventions which monitor and track HRQL over
time among Aboriginal people who inject drugs with chronic HCV.
Even with the advent of interferon-free all-oral HCV treatments,
psychosocial and socioeconomic factors will likely continue to be a
signiﬁcant barrier to treatment uptake for people who inject drugs
(Higgs, Wright, & Hellard, 2016). We argue that there is a need for
nursing led and focused HCV interventions which could improve
the physical and mental HRQL for Aboriginal Australians. Engagement in HCV diagnosis, treatment, and care may also result in better
self-management and care of the long-term consequences of HCV
infection within the Aboriginal community. Data from our study
suggest attention to preventive care and strategies to reduce excessive alcohol consumption are also required. Ultimately this could
result in the establishment of HCV community clinics in Aboriginal health care settings with trained Aboriginal community health
nurses who can provide support, encourage drug users to assess
their liver health and subsequently undertake HCV treatment in a
culturally appropriate way.
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